Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 31Myelodysplastic Syndromes 7Leukemia 4Congenital Abnormalities 4Mastocytosis, Systemic 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Leukemia, Mast-Cell 2Aggression 2Recurrence 1Rectal Neoplasms 1Mastocytosis 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1GATA2 Deficiency 1Blast Crisis 1

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × midostaurin × Clear all
NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Novartis

Phase 3 Completed
511 enrolled 26 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Novartis

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡